Literature DB >> 8958892

Salmeterol tachyphylaxis in steroid treated asthmatic subjects.

H Booth1, R Bish, J Walters, F Whitehead, E H Walters.   

Abstract

BACKGROUND: Tachyphylaxis to the protection afforded by salmeterol to broncho-constrictor stimuli after regular use has been described in patients with mild asthma not receiving inhaled corticosteroids. The present study was performed to investigate whether airway tachyphylaxis occurs in symptomatic asthmatic subjects receiving inhaled corticosteroids, the group for whom salmeterol is recommended in clinical practice.
METHODS: Thirty one adult patients with symptomatic chronic asthma who were receiving inhaled corticosteroids were randomised in a double blind manner and on a 2:1 basis to receive salmeterol 50 micrograms (n = 22) or placebo (n = 9) twice daily. Baseline forced expiratory volume in one second (FEV1) was measured during the run-in period, on day 0, and after four and eight weeks of regular treatment (following a 36 hour test drug washout period). Airway responsiveness to methacholine was measured one hour after administration of the test drug on these occasions. Diary cards were kept throughout the study and for a two week follow up period.
RESULTS: Baseline FEV1 was not significantly different between the treatment groups or between visits. There was significant bronchodilatation one hour after salmeterol administration at 0, four, and eight weeks. No significant tachyphylaxis of the bronchodilator action of salmeterol was seen. Protection against methacholine induced bronchoconstriction reduced from 3.3 doubling dilutions after the first dose of salmeterol to two doubling dilutions after four and eight weeks of regular treatment. Symptom scores and "rescue" salbutamol use were significantly reduced during salmeterol treatment and daytime improvements were maintained into the follow up period.
CONCLUSIONS: Inhaled corticosteroids did not prevent tachyphylaxis to the protection afforded by salmeterol to methacholine induced bronchoconstriction. The clinical significance, if any, of these findings remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958892      PMCID: PMC1090520          DOI: 10.1136/thx.51.11.1100

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

1.  Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma.

Authors:  B J O'Connor; S L Aikman; P J Barnes
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

2.  Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.

Authors:  B J Lipworth; A D Struthers; D G McDevitt
Journal:  Am Rev Respir Dis       Date:  1989-09

3.  Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.

Authors:  J E Harvey; A E Tattersfield
Journal:  Thorax       Date:  1982-04       Impact factor: 9.139

4.  beta-adrenergic agonist resistance in normal human airways.

Authors:  S T Holgate; C J Baldwin; A E Tattersfield
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

5.  Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction.

Authors:  M Solèr; L Joos; C T Bolliger; S Elsasser; A P Perruchoud
Journal:  Eur Respir J       Date:  1994-11       Impact factor: 16.671

6.  Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.

Authors:  B Lundback; D W Rawlinson; J B Palmer
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

7.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.

Authors:  D S Pearlman; P Chervinsky; C LaForce; J M Seltzer; D L Southern; J P Kemp; R J Dockhorn; J Grossman; R F Liddle; S W Yancey
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

8.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.

Authors:  D Cheung; M C Timmers; A H Zwinderman; E H Bel; J H Dijkman; P J Sterk
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

9.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.

Authors:  E Reihsaus; M Innis; N MacIntyre; S B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  1993-03       Impact factor: 6.914

Review 10.  Fetal pulmonary beta-adrenergic receptors: characterization in the human and in vitro modulation by glucocorticoids in the rabbit.

Authors:  J M Roberts; M M Jacobs; J B Cheng; P J Barnes; A T O'Brien; P J Ballard
Journal:  Pediatr Pulmonol       Date:  1985 May-Jun
View more
  25 in total

Review 1.  Interactions between corticosteroids and beta agonists.

Authors:  D R Taylor; R J Hancox
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.

Authors:  J A van Noord; A J Schreurs; S J Mol; P G Mulder
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 3.  Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 5.  Antagonism of long-acting beta2-adrenoceptor agonism.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 6.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 7.  Interactions between corticosteroids and beta2-agonists.

Authors:  Robert J Hancox
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 8.  Agonist efficacy and receptor desensitization: from partial truths to a fuller picture.

Authors:  Steven J Charlton
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

Review 9.  Inhaled innate immune ligands to prevent pneumonia.

Authors:  Scott E Evans; Michael J Tuvim; Cory J Fox; Nidhi Sachdev; Leonid Gibiansky; Burton F Dickey
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

10.  Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist.

Authors:  James P Kemp
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.